市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | BridgeBio Pharma, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.25 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.97% |
| 机构持股比例 | 98.14% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Viking Global Investors Lp | 30 Jun 2025 | 18,555,375 |
| Kohlberg Kravis Roberts & Co. L.P. | 30 Jun 2025 | 13,260,971 |
| Farallon Capital Management Llc | 30 Jun 2025 | 7,900,000 |
| Aisling Capital Management Lp | 30 Jun 2025 | 6,068,125 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 95.00 (Cantor Fitzgerald, 75.08%) | 购买 |
| 中 | 70.00 (29.01%) | |
| 低 | 57.00 (Scotiabank, 5.05%) | 购买 |
| 平均值 | 70.57 (30.06%) | |
| 总计 | 7 购买 | |
| 平均价格@调整类型 | 49.26 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Raymond James | 21 Oct 2025 | 59.00 (8.74%) | 购买 | 54.36 |
| HC Wainwright & Co. | 15 Sep 2025 | 70.00 (29.01%) | 购买 | 51.47 |
| 03 Sep 2025 | 70.00 (29.01%) | 购买 | 51.84 | |
| UBS | 12 Sep 2025 | 82.00 (51.12%) | 购买 | 51.21 |
| JP Morgan | 03 Sep 2025 | 70.00 (29.01%) | 购买 | 51.84 |
| Oppenheimer | 06 Aug 2025 | 61.00 (12.42%) | 购买 | 44.81 |
| Scotiabank | 06 Aug 2025 | 57.00 (5.05%) | 购买 | 44.81 |
| Cantor Fitzgerald | 29 Jul 2025 | 95.00 (75.08%) | 购买 | 46.32 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合